文献速递精神分裂症与精神病性障碍

抗精神病药中长期代谢副作用:随机对照试验网络Meta分析

Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.
PubMed 文献 · World Psychiatry · 2023-01-01

该研究采用随机效应贝叶斯网络Meta分析,纳入137项研究(35,007例精神分裂症患者),评估31种抗精神病药中长期代谢副作用。结果显示,氯丙嗪增重最多(较安慰剂平均差5.13 kg),氯氮平、奥氮平、佐替平次之;增重明显的药物在空腹血糖和血脂参数上往往也更差,证据置信度低至中等。

要点

  • 氯丙嗪增重最多(5.13 kg),氯氮平、奥氮平、佐替平次之。
  • 增重明显的药物在空腹血糖和血脂参数上也往往更差。
  • 中长期数据对药物选择应比短期数据更受重视。

核心结论

  • 抗精神病药在中长期治疗中引起代谢副作用倾向不同,选药时应优先考虑中长期数据。

研究设计与样本

  • 随机效应贝叶斯网络Meta分析,检索Cochrane精神分裂症组试验注册库(截至2020年4月27日)和PubMed(截至2021年6月14日)。
  • 纳入研究时长>13周的随机对照试验,比较31种抗精神病药或安慰剂,共137项试验、35,007例精神分裂症患者,中位随访45周。

主要发现

  • 氯丙嗪较安慰剂增重平均差5.13 kg(95% CrI 1.98至8.30),氯氮平4.21 kg(95% CrI 3.03至5.42),奥氮平3.82 kg(95% CrI 3.15至4.50),佐替平3.87 kg(95% CrI 2.14至5.58)。
  • 增重较多的药物往往在空腹血糖和血脂参数上结果也更差。
  • 敏感性分析和网络Meta回归分析未显著改变结果,但富集设计、药企赞助和观察病例数据替代意向性分析数据在一定程度上改变了增重平均差。

关键数值与推荐

  • 主要结局为增重(kg),次要结局包括增重人数、空腹血糖、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯。
  • 证据置信度范围为低至中等。

临床怎么用

  • 对需中长期抗精神病药治疗的精神分裂症患者,选药时应考虑药物代谢副作用差异,优先参考中长期数据而非短期数据。

局限性

  • 证据置信度范围为低至中等。
  • 富集设计、药企赞助和观察病例数据替代意向性分析数据对增重平均差有一定影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic side effects of antipsychotic drugs can have serious health consequences and may increase mortality. Although persons with schizophrenia often take these drugs for a long time, their mid- to long-term metabolic effects have been studied little so far. This study aimed to evaluate the mid- to long-term metabolic side effects of 31 antipsychotics in persons with schizophrenia by applying a random-effects Bayesian network meta-analysis. We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (up to April 27, 2020) and PubMed (up to June 14, 2021). We included published and unpublished, open and blinded randomized controlled trials with a study duration >13 weeks which compared any antipsychotic in any form of administration with another antipsychotic or with placebo in participants diagnosed with schizophrenia. The primary outcome was weight gain measured in kilograms. Secondary outcomes included "number of participants with weight gain", fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. We identified 137 eligible trials (with 35,007 participants) on 31 antipsychotics, with a median follow-up of 45 weeks. Chlorpromazine produced the most weight gain (mean difference to placebo: 5.13 kg, 95% credible interval, CrI: 1.98 to 8.30), followed by clozapine (4.21 kg, 95% CrI: 3.03 to 5.42), olanzapine (3.82 kg, 95% CrI: 3.15 to 4.50), and zotepine (3.87 kg, 95% CrI: 2.14 to 5.58). The findings did not substantially change in sensitivity and network meta-regression analyses, although enriched design, drug company sponsorship, and the use of observed case instead of intention-to-treat data modified the mean difference in weight gain to some extent. Antipsychotics with more weight gain were often also among the drugs with worse outcome in fasting glucose and lipid parameters. The confidence in the evidence ranged from low to moderate. In conclusion, antipsychotic drugs differ in their propensity to induce metabolic side effects in mid- to long-term treatment. Given that schizophrenia is often a chronic disorder, these findings should be given more consideration than short-term data in drug choice.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Burschinski A, Schneider-Thoma J, Chiocchia V, et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry. 2023. PMID: 36640396. doi:10.1002/wps.21036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。